Re: Sotyktu/Deucra Abstract Titles at ACR2022 10-14Nov2022
you are correct i am mixing the metaphor a bit so to speak, but i do think of gi intolerance - and it is significant - as safety though intolerance is more accurate. nonetheless it really does limit usage and the dose escalation pack needed to initial treatment tacitly confirms its significance. now as to deucra safety - lets not conflate the fda label language with what was seen in the trials (yes real world data is needed to confirm) which was really really good. imho the label language is hangover from experience with the "classic jaks". time will tell of course but i stand by my opinion i would try deucra first if i were a patient and conflict of interest disclosed, would prescribe it readily to my patients if i was still in practice.